Get This Insiders Info On The Bortezomib Before You Are Too Late

S. Weber13, A. Patnaik14, M. Dolled-Filhart2, K. Emancipator2, S. Peter Kang2, S. Ebbinghaus2, K. Anderson2, T. C. Gangadhar15 1Mayo Clinic, Jacksonville, FL, USA2Merck & Co., Inc., Whitehouse Station, NJ, USA3Memorial Sloan Kettering Cancer Center, New York, NY, USA4Princess Margaret Cancer Centre, Toronto, ON, Canada5University of California Los Angeles, Los Angeles, CA, USA6Dana-Farber Cancer Institute, Boston, MA, USA7The Angeles Clinic and Research Institute, Los Angeles, CA, USA8Gustave Roussy and INSERM U 981, Villejuif, France9University of California San Francisco, San Francisco, CA, USA10The University https://www.selleckchem.com/products/Bortezomib.html of Texas MD Anderson Cancer Center, Houston, TX, USA11Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia, Sydney, NSW, Australia12University of Sydney, Sydney, NSW, Australia13H. Lee Moffitt Cancer Center, Tampa, FL, USA14Mayo Clinic, Rochester, MN, USA15Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, https://www.selleckchem.com/products/sch772984.html USA Previously, we demonstrated that BTS is independently associated with OS and ORR in pts with MM treated with pembro. Herein, we extend the analysis to test whether PD-L1 expression is independently associated with OS and ORR and whether BTS remains independent when PD-L1 is included in the analysis. All pts with MM treated with pembro in KEYNOTE-001 were included. PD-L1 expression was assessed in pretreatment tumor biopsies by IHC using the 22C3 antibody; positivity https://www.selleck.cn/products/gdc-0068.html was defined as staining in ��1% of tumor cells. Univariate analysis of BTS, PD-L1 expression, and clinical factors was performed via log-rank (OS) or proportion (ORR) testing. Multivariate analysis was assessed using Cox regression. PD-L1 status was known for 275 (67%) of 411 pts treated with pembro, with 78% PD-L1+ and 22% PD-L1-. Pts who received prior ipilimumab (IPI) were more likely to be PD-L1+ (84% of IPI treated vs 71% of IPI naive; P?=?0.017). Prior IPI was also associated with increased BTS. Neither prior BRAF inhibitor therapy nor BTS was associated with PD-L1 status. In a multivariate analysis, BTS below the median (HR, 0.32; P?